Multiplex PCR of BCR-ABL1 transcript variants in CML patients... | Download Scientific Diagram
The Philadelphia chromosome in leukemogenesis | Cancer Communications | Full Text
Characterization and monitoring by droplet digital PCR of a novel BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia
Response and Resistance to BCR-ABL1-Targeted Therapies - ScienceDirect
Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease | Leukemia
Persistence of LSCs: BCR-ABL1 kinase-dependent and -independent pathways. | Download Scientific Diagram
Myeloproliferative neoplasms with concurrent BCR–ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group | Modern Pathology
Frontiers | BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
Frontiers | Genomic Copy Number Variants in CML Patients With the Philadelphia Chromosome (Ph+): An Update
Cancers | Free Full-Text | Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Response and Resistance to BCR-ABL1-Targeted Therapies - ScienceDirect
Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia | NEJM
Persistence of LSCs: BCR-ABL1 kinase-dependent and -independent pathways. | Download Scientific Diagram
Precision Medicine in BCR-ABL1 Negative Myeloproliferative Neoplasms | Published in healthbook TIMES Oncology Hematology
Cancers | Free Full-Text | Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia
IJMS | Free Full-Text | Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far?
Change in BCR-ABL1 IS over time based on achievement of BCR-ABL1 IS 10%... | Download Scientific Diagram
Pharmaceutics | Free Full-Text | BCR-ABL1 Tyrosine Kinase Complex Signaling Transduction: Challenges to Overcome Resistance in Chronic Myeloid Leukemia
Measurable residual disease in chronic myeloid leukemia | Haematologica
Measurable residual disease in chronic myeloid leukemia | Haematologica
Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib? – ScienceOpen
Flow Cytometric Immunobead Assay for Detection of BCR-ABL1 Fusion Proteins in Chronic Myleoid Leukemia: Comparison with FISH and PCR Techniques | PLOS ONE
Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR -ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended | PLOS ONE
BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat? - Chiaretti - 2019 - Cancer - Wiley Online Library
Frontiers | A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs
